Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1

Conditions

Ovarian Neoplasms 11Prostatic Neoplasms 7Fallopian Tube Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1SCLC,Extensive Stage 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Lung Neoplasms 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

Fulvestrant 64Letrozole 54Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Anastrozole 34Carboplatin 33Tamoxifen 32exemestane 30pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Biopsy 19Radiotherapy 18olaparib 17Blood Specimen Collection 17Standard of Care 16Docetaxel 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13Methods 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × niraparib × 90 days × Clear all
NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
62 enrolled
Breast

Breast Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 2 Recruiting
484 enrolled
Breast

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡